Text Size

Presbyopia in Breast Cancer Survivors

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by:
Alberta Health Services
ClinicalTrials.gov Identifier:
NCT00271661
First received: December 30, 2005
Last updated: December 8, 2011
Last verified: December 2011
History of Changes
  Purpose

Chemotherapy drugs, used in cancer treatments, may change the timing of a vision condition known as presbyopia. Presbyopia is the inability to focus the eye on close objects, by a process called accommodation. It is caused by an increase in the stiffness of the lens of the eye that occurs naturally with aging. Currently, there are no known treatments that can be used to prevent or delay presbyopia. As a result, the risk, in later life, of having this condition is essentially 100%.

The purpose of this research is to determine whether chemotherapy drugs are delaying the age at which people develop symptoms of presbyopia. We hope to establish that presbyopia can in fact be delayed with the use of drugs, which would ultimately lead to further research in this area.


Condition
Presbyopia

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Presbyopia in Breast Cancer Survivors

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Alberta Health Services:

Enrollment: 0
Study Start Date: August 2005
Estimated Study Completion Date: May 2006
Detailed Description:

Chemotherapy drugs, used in cancer treatments, may change the timing of a vision condition known as presbyopia. Presbyopia is the inability to focus the eye on close objects, by a process called accommodation. It is caused by an increase in the stiffness of the lens of the eye that occurs naturally with aging. Currently, there are no known treatments that can be used to prevent or delay presbyopia. As a result, the risk, in later life, of having this condition is essentially 100%.

The purpose of this research is to determine whether chemotherapy drugs are delaying the age at which people develop symptoms of presbyopia. We hope to establish that presbyopia can in fact be delayed with the use of drugs, which would ultimately lead to further research in this area.

  Eligibility

Ages Eligible for Study:   45 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

primary care clinic

Criteria

Inclusion Criteria:

  • ages 45-60
  • ability to understand and provide written consent in English

Exclusion Criteria:

  • blindness
  • visual defects leading to accommodative failure
  • severe myopia
  • recurrent breast cancer
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00271661

Sponsors and Collaborators
Alberta Health Services
Investigators
Principal Investigator: John Mackey, Dr. Alberta Health Services
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00271661     History of Changes
Other Study ID Numbers: BR-1-0072, ETHICS 22007
Study First Received: December 30, 2005
Last Updated: December 8, 2011
Health Authority: Canada: Health Canada

Keywords provided by Alberta Health Services:
presbyopia; breast cancer survivors

Additional relevant MeSH terms:
Breast Neoplasms
Presbyopia
Neoplasms by Site
Neoplasms
 Breast Diseases
Skin Diseases
Refractive Errors
Eye Diseases

ClinicalTrials.gov processed this record on May 22, 2013